Related references
Note: Only part of the references are listed.Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
Virginia Ferraresi et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives
Andrea Alberti et al.
FRONTIERS IN ONCOLOGY (2022)
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
N. D. Gross et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Neoadjuvant immunotherapy for melanoma
Ann Y. Lee et al.
JOURNAL OF SURGICAL ONCOLOGY (2021)
Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
Mithunah Krishnamoorthy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma
Curtis R. Pickering et al.
CLINICAL CANCER RESEARCH (2014)